Trial comparisons

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=88

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01877915-deaths",
        "title": "Rivaroxaban vs Placebo: deaths from any cause",
        "summary": "565 of 2507 against 571 of 2515; risk difference -0.2 points, 95% interval -2.5 to 2.1; NCT01877915, A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",
        "record": "/library/comparisons/NCT01877915-deaths",
        "nct_id": "NCT01877915",
        "kind": "deaths",
        "participants": 5022,
        "risk_difference": {
          "value": -0.0016688064671405156,
          "lower": -0.02480583654099521,
          "upper": 0.021473109313890595
        },
        "group_1": "565 of 2,507",
        "group_2": "571 of 2,515",
        "difference": "-0.2 points",
        "interval": "-2.5 to 2.1",
        "trial_title": "A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure"
      },
      {
        "id": "NCT01877915-sae",
        "title": "Rivaroxaban vs Placebo: serious adverse events",
        "summary": "479 of 2507 against 451 of 2515; risk difference 1.2 points, 95% interval -1.0 to 3.3; NCT01877915, A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",
        "record": "/library/comparisons/NCT01877915-sae",
        "nct_id": "NCT01877915",
        "kind": "serious-adverse-events",
        "participants": 5022,
        "risk_difference": {
          "value": 0.01174096228373675,
          "lower": -0.00975214354048316,
          "upper": 0.03322857501489479
        },
        "group_1": "479 of 2,507",
        "group_2": "451 of 2,515",
        "difference": "1.2 points",
        "interval": "-1.0 to 3.3",
        "trial_title": "A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=89",
  "request_id": "JCyxReT-36ukIpjh"
}